^
    1d
    Physiologically-Based Pharmacokinetics of Ribociclib Drug-Drug Interactions and Organ Impairment Pharmacokinetics in Early Breast Cancer. (PubMed, Pharmaceuticals (Basel))
    PBPK modeling predicted that ritonavir or erythromycin (strong and moderate CYP3A4 inhibitors) would increase ribociclib steady-state area under the concentration-time curve (AUC) by 1.84-fold or show no meaningful impact, respectively. Steady-state ribociclib AUC was estimated to decrease by 83% and 74% with rifampicin and efavirenz, strong and moderate CYP3A4 inducers, respectively. Ribociclib was estimated to increase CYP3A4 substrate midazolam exposure by 280%. Mild HI or mild/moderate RI did not show an apparent impact on ribociclib PK. Using relevant data and methodology for EBC patients, this analysis informed the approved ribociclib label of no dose adjustment for EBC patients with concomitant use of a moderate CYP3A inhibitor, any degree of HI, or mild/moderate RI, and a reduced 200 mg dose for patients with concomitant use of a strong CYP3A inhibitor or severe RI.
    PK/PD data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Kisqali (ribociclib) • efavirenz • midazolam hydrochloride • rifampicin • ritonavir
    4d
    Impact of rifampicin on P-glycoprotein (ABCB1) expression in M1 and M2 macrophages derived from the THP-1 monocytic cell line or peripheral blood mononuclear cells. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    In conclusion, ABCB1 expression in macrophages differs by the cell model (THP-1 cell line vs. primary PBMC) and the polarization phenotype (M1 vs. M2). Strong rifampicin-mediated enhancements of ABCB1 were only observed in THP-1-derived M1 and M2 cells.
    Preclinical • Journal
    |
    IFNG (Interferon, gamma) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • IL13 (Interleukin 13) • IL4 (Interleukin 4) • SLCO2B1 (Solute Carrier Organic Anion Transporter Family Member 2B1)
    |
    rifampicin
    6d
    Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis (clinicaltrials.gov)
    P1, N=72, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Jan 2026 --> May 2026 | Trial primary completion date: Jan 2026 --> May 2026
    Trial completion date • Trial primary completion date
    |
    rifampicin
    10d
    Co-SAM: An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (clinicaltrials.gov)
    P3, N=674, Active, not recruiting, Queen Mary University of London | Trial completion date: Sep 2027 --> Aug 2026 | Trial primary completion date: Feb 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    rifampicin
    20d
    A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet (clinicaltrials.gov)
    P1, N=28, Recruiting, Guangzhou Lupeng Pharmaceutical Company LTD. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    itraconazole • rifampicin • rocbrutinib (LP-168)
    20d
    Primary Pericardial Angiosarcoma Demonstrating Initial Response Followed by Progression on First-Line Chemotherapy: A Case Report. (PubMed, Clin Case Rep)
    Based on trace Mycobacterium tuberculosis detection on sputum GeneXpert with indeterminate rifampicin resistance, the patient was initially diagnosed and treated as tuberculous pericarditis...The patient received first-line chemotherapy with ifosfamide and epirubicin...Second-line chemotherapy with nab-paclitaxel and gemcitabine was subsequently initiated, with planned response assessment after 3 cycles...Although substantial initial responses to chemotherapy may occur, the disease remains highly aggressive with a high risk of progression. Early histopathological diagnosis and timely initiation of adaptive, multimodal treatment strategies are critical to optimizing clinical outcomes.
    Journal
    |
    CD34 (CD34 molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    gemcitabine • albumin-bound paclitaxel • ifosfamide • epirubicin • rifampicin
    27d
    Co-SAM: An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (clinicaltrials.gov)
    P3, N=674, Active, not recruiting, Queen Mary University of London | Recruiting --> Active, not recruiting | N=1266 --> 674 | Trial primary completion date: Jul 2026 --> Feb 2026
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    rifampicin
    28d
    P1-IMU838DDI-CYP2C8: A Phase 1, Single-Center, Open-Label, Fixed-Sequence, 2-Part Study to Assess the Pharmacokinetics of IMU-838 Administered Alone and in Combination with Multiple Doses of Gemfibrozil as CYP2C8 Inhibitor, or Rifampicin as CYP2C8 Inducer, in Healthy Subjects (2025-521754-41-00)
    P1, N=24, Active, not recruiting, Immunic AG | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    rifampicin
    1m
    Mechanical Bowel Preparation With or Without Oral Antibiotics in Left Sided Colorectal Cancer Surgery (clinicaltrials.gov)
    P=N/A, N=60, Enrolling by invitation, Shaukat Khanum Memorial Cancer Hospital & Research Centre
    New trial
    |
    rifampicin
    1m
    Drug Interaction and Food Effect Study of CS0159 (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, Cascade Pharmaceuticals, Inc
    New P1 trial
    |
    itraconazole • rifampicin
    1m
    Differential gene regulation by SR12813 and rifampicin: Insights into PXR and PPARγ activation and metabolic pathway modulation in LS180 colon cancer cells. (PubMed, Drug Metab Dispos)
    SIGNIFICANCE STATEMENT: SR12813 activates both pregnane X receptor and peroxisome proliferator-activated receptor gamma, demonstrating dual nuclear receptor modulation in colon cancer cells. By linking xenobiotic metabolism with lipid and mitochondrial pathways, this work uncovers previously unreported receptor crosstalk and provides a mechanistic framework for how diverse ligands can differentially shape transcriptional programs relevant to drug metabolism and tumor biology.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • NR1I2 (Nuclear Receptor Subfamily 1 Group I Member 2)
    |
    rifampicin
    1m
    Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours (clinicaltrials.gov)
    P1, N=64, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Recentin (cediranib) • rifampicin